Security key
007002108
Adicet Bio, Inc. - Common Stock, par value $0.0001 (ACET)
CUSIP: 007002108
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.0001
- Total 13F shares
- 63,950,445
- Total 13F value
- $77,407,916
- Share change
- -11,212,870
- Put/Call ratio
- 844%
- SEC-reported price per share
- $1.21
- Number of holders
- 83
- Value change
- -$23,984,627
- Number of buys
- 44
- Number of sells
- 55
- Shares outstanding
- 9,599,852
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
83
Top holders
10
ACET full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Adicet Bio, Inc. SEC filings
Adicet Bio, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 007002108
Recent filing periods:
Ownership snapshot
Top reported holders of ACET - Adicet Bio, Inc. - Common Stock, par value $0.0001 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ORBIMED ADVISORS LLC
Disclosed value leader
ORBIMED ADVISORS LLC
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 119%
Showing 1-6 of 15 holder rows.
Quick read
ORBIMED ADVISORS LLC leads the comparable SEC ownership view at 119%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens ORBIMED ADVISORS LLC's linked filing trail.
Comparable ownership
Top 5
ORBIMED ADVISORS LLC
119%
RA CAPITAL MANAGEMENT, L.P.
79%
TANG CAPITAL MANAGEMENT LLC
67%
BALYASNY ASSET MANAGEMENT L.P.
64%
RTW INVESTMENTS, LP
43%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC |
13F
Company
|
119%
|
$26,900,779
11,447,140 shares
|
— | 31 Mar 2024 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
79%
|
$17,721,350
7,541,000 shares
|
— | 31 Mar 2024 |
| TANG CAPITAL MANAGEMENT LLC |
13F
Company
|
67%
|
$15,057,390
6,407,400 shares
|
— | 31 Mar 2024 |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
Company
|
64%
|
$14,526,927
6,181,671 shares
|
— | 31 Mar 2024 |
| RTW INVESTMENTS, LP |
13F
Company
|
43%
|
$9,716,383
4,134,631 shares
|
— | 31 Mar 2024 |
| MILLENNIUM MANAGEMENT LLC |
13F
Company
|
43%
|
$9,649,500
4,106,170 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
83
Shares
63,950,445
Rows available
83
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
96
Q2 2024 holders
83
Holder diff
-13
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend